What Lessons Can We Learn From Colorado’s Marijuana Laws?


Colorado became one of the first states to legalize recreational marijuana in 2013. 

How has this policy affected health concerns such as the opioid epidemic, the use of cannabidiol (CBD), in-utero exposure, and teen vaping and marijuana use? 

As Texas continues to battle the opioid epidemic, and as lawmakers prepare for another legislative session in 2021, what lessons can you learn from Colorado’s decision on marijuana? 

The Texas Medical Association has created a new webinar – Marijuana and Colorado: A Look at Marijuana and the Opioid Crisis – that is designed to help you: 

  • Analyze the basic science of the endocannabinoid systems actions on the opioid receptors;
  • Describe the current medical evidence, positive and negative, as to the effects of cannabis and CBD oil on pain; and
  • Evaluate updates on the Colorado experience and issues in Texas regarding the opioid epidemic, cannabis, and CBD oil. 

The webinar is presented by Kenneth Finn, MD, who served on the Colorado governor’s Amendment 64 Implementation Task Force Consumer Safety and Social Issues Work Group, and the Colorado Medical Marijuana Scientific Advisory Council.

Dr. Finn is a graduate of the University of Texas at Houston and he completed his residency in physical medicine and rehabilitation at the University of Utah in Salt Lake City. He is board certified in physical medicine and rehabilitation and pain medicine. 

The webinar is accredited for 1.5 AMA PRA Category 1 Credits™. 

As with most of TMA’s CME programs, Marijuana and Colorado: A Look at Marijuana and the Opioid Crisis is free for TMA members and their practice staff thanks to a generous sponsorship by the Texas Medical Association Insurance Trust

TMA policy does not endorse state-based medical cannabis programs, the legalization on marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product. TMA policy does support: 

  • More scientific studies of marijuana and related cannabinoids for potential medical uses, particularly in patients with serious conditions where evidence suggests possible effective treatment or the better understanding of disease;
  • Evidence-based strategies that will help to reduce use the use of marijuana, especially by those who are at high risk – children, pregnant women, etc.;
  • Identifying resources for physicians on the research relating to marijuana for medical use and working with specialty societies to guide education and information that should be shared with patients; and
  • Affirming the physician’s right to discuss with patients any and all possible treatment options, including the use of marijuana, without the threat to physician or patient of regulatory, disciplinary, or criminal sanctions.

Last Updated On

June 12, 2020

Originally Published On

June 12, 2020

Related Content